Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 646-650

  Portal, Jose A Rodríguez ^a   Becerra, Eulogio Rodríguez ^a   Rodríguez, David ^a   Michavila, Inmaculada Alfageme ^b   Martínez, Aida Quero ^c   Roza, Carmen Diego ^f   Jiménez, Antonio León ^d   Montes, Isabel Isidro ^c   Rivas, Pilar Cebollero ^e  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c National Institute of Silicosis   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^e Universidad Pública de Navarra   (Spain)

^f Universidad de La Coruña   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BIOLOGICAL MARKER; MESOTHELIN; PROTEIN SMRP; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADULT; AREA UNDER CURVE; ASBESTOSIS; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 60549101347     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0422     Document Type: Article

References (18)

1. Pass HI, Volgelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer 2004;28:93-174.
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
3. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Rev 2006;12: 447-53.
4. Robinson BWS, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
5. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
6. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007; 53:666-72.
7. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008;61:235 -43.
8. Programa integral de vigilancia de la salud de los trabajadores que han estado expuestos a amianto y protocolo de vigilancia sanitaria específica. Revisión 2003: Ministerio de Sanidad y Consumo; 2003.
9. Isidro Montes I, Abu Shams K, Alday E, et al. Normativa sobre el asbesto y sus enfermedades pleuropulmonares. Arch Bronconeumol 2005;41:153-68.
10. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-93.
11. Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13:339-443.
12. Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005;19:1025-40.
13. Robinson Bw, Creaney J, Lake R, et al. Soluble mesothelin-related protein - a blood test for mesothelioma. Lung Cancer 2005;49: S109-11.
14. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-81.
15. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239 -46.
16. Pass H, Wolaniuk D, Wali A, et al. Soluble mesothelin related peptides: a potential biomarker for malignant pleural mesothelioma [abstract]. J Clin Oncol 2005;23:9532.
17. Hagiwara Y, Hamada Y, Kuwahara M, et al. Establishment of a novel specific ELISA systemfor rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma. Cancer Sci 2008;99:666-70.
18. Okio H, Kazu S, Masahiro M. Diagnostic biomarker of asbestos-related mesothelioma: example of translational research. Cancer Sci 2007;98:1147-51.